Dr. Craig Earle is The Partnership’s Cancer Control Division implements programs and initiatives that deliver on the priorities of the 2019-2029 Canadian Strategy for Cancer Control. The division is comprised of program teams that specialize in all parts of the cancer continuum – prevention, screening, diagnosis, treatment, clinical care, survivorship and palliative care.
He came to the Partnership from the Ontario Institute for Cancer Research (OICR) where he was the Head of Clinical Translation. His clinical practice is at Sunnybrook Hospital's Odette Cancer Centre. He is also a former director of the Health Services Research Program for Cancer Care Ontario (CCO). His personal research interests focus on evaluating and improving the quality of care received by advanced cancer patients and cancer survivors, the effects of financial incentives on care delivery, and making linked, de-identified administrative data more available for health research.
Dr. Earle is a Professor in the Department of Medicine at the University of Toronto. He is also a member of the pan-Canadian Oncology Drug Review Expert Review Committee, the inaugural and past Chair of the Ontario Steering Committee for Cancer Drug Programs, past Cancer Program Leader at the Institute for Clinical Evaluative Sciences, and past Co-Chair of the Ontario Cancer System Quality Index Project Leadership Team.
Originally from Ottawa, Ontario, Dr. Earle spent 10 years at the Dana-Farber Cancer Institute and Brigham & Women’s Hospital in Boston, Massachusetts. During his time in Boston, he was an Associate Professor of Medicine at Harvard Medical School and an Associate Professor of Health Policy and Management at the Harvard School of Public Health before returning to Ontario in 2008. He was also the founding director of the Lance Armstrong Foundation Adult Survivorship Clinic at Dana-Farber.
Areas of Expertise (3)
Health Services Research
Sunnybrook Health Sciences Centre Mentorship Award (professional)
Sunnybrook Health Sciences Centre's Department of Medicine - William J. Sibbald Faculty Mentorship Award
Society of General Internal Medicine Distinction (professional)
Society of General Internal Medicine (SGIM). (Distinction) Distinguished Professor of Cancer Research
Fellow of the American Society of Clinical Oncology (professional)
Fellow of the American Society of Clinical Oncology from the American Society of Clinical Oncology. (Distinction)
University of Toronto Quality Improvement Award (professional)
University of Toronto's Division of Medical Oncology - Quality Improvement Award
Ontario Institute for Cancer Research (OICR) Investigator Award (professional)
2013-2018: Awarded to Dr. Craig Earle. The program provides stable recruitment and retention funding for principal investigators in Ontario, further strengthening the province’s cancer research capacity.
Sunnybrook Health Sciences Centre Senior Investigator Award (professional)
Senior Investigator Award at Sunnybrook Health Sciences Centre (Research Award)
University of Ottawa: M.Sc., Epidemiology 1998
University of Ottawa: MD, Medicine 1990
University of Ottawa: B.Sc., Biochemistry 1989
- Scientist, Evaluative Clinical Sciences, Odette Cancer Research Program, Sunnybrook Research Institute
- Head, clinical translation, Ontario Institute for Cancer Research
- Professor, department of medicine, University of Toronto
- Senior scientist and cancer program leader, Institute for Clinical and Evaluative Sciences
- Medical oncologist, gastrointestinal oncology, Sunnybrook Health Sciences Centre
Media Appearances (2)
The dangers of smoking with cancer (video)
Breakfast Television Toronto tv
See link to video This week is National Non-Smoking Week, and we're talking to VP of Cancer Control at the Partnership Against Cancer, Dr. Craig Earle, on the effects of smoking on people who have cancer.
Weighing the merits of ‘never-say-die’ oncology
National Post print
Close to one in four patients studied received potentially aggressive care in their last month, it found. Care of all kinds in the last months of life generally costs the health-care system billions of dollars a year, other research has suggested. The oncologist who led the Ontario study, Dr. Craig Earle of Toronto's Sunnybrook Health Sciences Centre, said hospice beds and palliative services in patients' homes are often not available. He and other experts advocate new government spending on palliative care, designed to lessen pain and discomfort and address psychological and spiritual issues for patients whose illness can no longer be treated.
Research Focus (1)
Health services research in cancer
Dr. Earle’s research program focuses on using administrative data to evaluate the accessibility, quality, costs and outcomes of care delivered to cancer patients and survivors.
Research Grants (3)
What is the impact of a provincial program to screen for symptoms on health service use?
Canadian Cancer Society Research Institute $193,417
Innovation Grant: 2016-2019
The prostate cancer program project in rapid development of novel diagnostic markers for early prostate cancer (PRONTO)
Prostate Cancer Canada $4,995,400
Movember Team Grant: 2014-2019
A population study of the toxicity and effectiveness of high-dose interferon for high-risk melanoma
Canadian Institutes of Health Research $360,993
Operating Grant: 2014-2017
Effects of socioeconomic status on esophageal adenocarcinoma stage at diagnosis, receipt of treatment, and survival: A population-based cohort studyPLoS One
2017 The incidence of esophageal adenocarcinoma (EAC) is increasing worldwide and has overtaken squamous histology in occurrence. We studied the impact of socioeconomic status (SES) on EAC stage at diagnosis, receipt of treatment, and survival. A population-based retrospective cohort study was conducted using Ontario Cancer Registry-linked administrative health data.
Cost-effectiveness analysis of treatment with non-curative or palliative intent for hepatocellular carcinoma in the real-world settingPLoS One
2017 Hepatocellular carcinoma (HCC) presentation is heterogeneous necessitating a variety of therapeutic interventions with varying efficacies and associated prognoses. Poor prognostic patients often undergo non-curative palliative interventions including transarterial chemoembolization (TACE), sorafenib, chemotherapy, or purely supportive care.
Has Province-Wide Symptom Screening Changed Opioid Prescribing Rates in Older Patients With Cancer?Journal of Oncology Practice
2017 Previous work in Ontario demonstrated that 33% of patients with cancer with severe pain did not receive opioids at the time of their pain assessment. With efforts to increase symptom screening and management since then, the objective of this study was to examine temporal trends in opioid prescribing.
Family Perspectives on Aggressive Cancer CareJournal of the American Medical Association (JAMA)
2016 Patients with advanced-stage cancer are receiving increasingly aggressive medical care near death, despite growing concerns that this reflects poor-quality care. The objective of this study was to assess the association of aggressive end-of-life care with bereaved family members' perceptions of the quality of end-of-life care and patients' goal attainment.
Quality of care for comorbid conditions during the transition to survivorship: Differences between cancer survivors and non-cancer controlsJournal of Clinical Oncology
2013 Building on previous research documenting differences in preventive care quality between cancer survivors and noncancer controls, this study examines comorbid condition care.
Geographic variation in physicians’ responses to a reimbursement changeNew England Journal of Medicine (NEJM)
2011 Although much research has revealed U.S. geographic variation in the intensity of health care utilization and the level of Medicare spending,1 such variation in response to Medicare policy changes has received much less attention. This limitation has become more important in the face of the myriad Medicare-reimbursement changes included in the Patient Protection and Affordable Care Act (ACA). This study looked at the variation in geographic response to a major reform of Medicare's reimbursement system for physician-administered drugs (Part B), the vast majority of which are chemotherapy agents.